Bold Therapeutics announced that the first patient for the company’s Phase 1b clinical trial has been enrolled at the Cross Cancer Institute.Read more
Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in breast cancer.
Bold Therapeutics recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.
Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).
Bold Therapeutics is excited to expand its COVID-19 consortium to include four additional collaborators from prominent institutions in Canada and the U.K.
Bold Therapeutics announced it has executed an option agreement with Hana Pharm Co. for BOLD-100 in South Korea.
Bold Therapeutics announced a research partnership with the University of Ottawato to explore the potential utility of BOLD-100 as a novel antiviral agent.
Bold Therapeutics announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.
Bold Therapeutics announced that it has received clearance from Health Canada to initiate a Phase 1b trial.
Bold Therapeutics will be visiting with multiple collaborators, vendors and partners in Europe from March 2nd to 6th.